FiercePharmaAsia—AZ’s China business; BeiGene CEO’s $28M pay; Kangmei’s $4.4B accounting error
AstraZeneca warned of slowing China growth after it lost a major government procurement deal for Crestor to a generic drugmaker. BeiGene’s CEO nabbed a $ 15 million special equity award in 2018 and ranked as biopharma’s second-highest-paid exec for the year. China’s Kangmei Pharma saw shares plummet on news that its shares could be delisted after a $ 4.4 billion accounting “error.” 1.… Read More »